This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
GIA announces the release of a comprehensive global report on Pharmaceutical Contract Manufacturing markets. Global market for Pharmaceutical Contract Manufacturing is forecast to reach US$23.4 million by 2020, spurred by pricing pressures and shrinking margins aggravated by patent expiries, regulatory and competitive pressures, and emergence of generics to replace blockbuster drugs nearing patent expiries.
San Jose, California (PRWEB) July 08, 2014
Global pharmaceutical contract manufacturing (PCM) market is witnessing steady growth, mirroring the positive trends in the broader pharmaceutical industry. Big pharma players, specialty players, medium-scale pharmaceutical companies, and biotech companies are increasingly channelizing resources to core operational areas of R&D and drug commercialization, while strategically offloading manufacturing and approval activities to third party service providers in order to eliminate CAPEX and OPEX burdens associated with manufacturing operations. The primary underlying factors driving this trend include increasingly stringent government regulations, fierce competition, and strong pricing pressure. Opportunities for pharmaceutical contract manufacturing is also growing, backed by factors such as patent expiries of blockbuster drugs, global healthcare reforms and infrastructure development, increasing focus of pharmaceutical companies on new drug development for complex diseases, and rapid growth in emerging markets.
As the pharmaceutical industry migrates from simple dosage formulations and active pharmaceutical ingredients to higher-priced complex formulations led by biologic drugs, pharmaceutical contract manufacturers (PCMs) are sharpening their manufacturing capabilities by adopting cutting-edge IT solutions, processes, and quality systems. Several market players are combining their competencies and augmenting their capabilities through strategic mergers and acquisitions in order to meet the manufacturing challenges of the rapidly growing biologics market. Complex dose forms such as sterile injectables and oral solid dose; large molecules such as nucleic acids, proteins, and peptides; and oncology therapeutics also require specialized manufacturing skills. The PCM market for vaccine remains nascent as drug developers tend to retain sophisticated vaccine manufacturing techniques in-house in order to protect proprietary technology, and keep a tight rein on product quality standards.
As stated by the new market research report on Pharmaceutical Contract Manufacturing, the United States represents the single-largest regional market worldwide and continues to grow, buoyed by the growth of the domestic pharma industry. Asia-Pacific ranks as the fastest growing market with a CAGR of 9.7% over the analysis period led by robust healthcare spending in China, India, Indonesia, Malaysia, Philippines, and Thailand. While solid-dose formulations remains the dominant market segment, low-volume and high margin injectable-dose formulations are growing at a robust pace, spurred by the plethora of biologics under development, migration from vials to flexible-bag and pre-filled syringes systems, and the growing demand for cytotoxic processing and other specialized services.
Major players covered in the report include AAIPharma Services Corporation, Aenova Group, Ajinomoto Althea Inc., Albany Molecular Research Inc., Boehringer Ingelheim GmbH, Catalent Pharma Solutions Inc., Cobra Biologics Holding AB, Dishman, DPx Holdings B.V., Famar Health Care Services, Haupt Pharma AG, Hospira Inc., Jubilant Life Sciences Limited, Kemwell Biopharma Pvt. Ltd., Lonza Group Ltd., NextPharma Technologies Holding Ltd., Nipro Pharma Corporation, and Recipharm AB, among others.
The research report titled Pharmaceutical Contract Manufacturing: A Global Strategic Business Report announced by Global Industry Analysts Inc., offers an in-depth assessment of market trends, growth drivers, challenges, technological trends, competition, mergers, acquisitions, and other strategic industry activities of major companies. Market estimates and projections in terms of service provider revenues are provided for major geographic markets, including the United States, Canada, Japan, Europe, Asia-Pacific, and Rest of World. The PCM market is further analyzed by major Dosage Forms, namely Injectables, Solid Dosage Forms, and Liquid & Semi-solid Dosage Forms.
For more details about this comprehensive market research report, please visit http://www.strategyr.com/Pharmaceutical_Contract_Manufacturing_Market_Report.asp.
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes 1500+ full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/
For the original version on PRWeb visit: http://www.prweb.com/releases/contract_manufacturing/pharmaceutical_industry/prweb12001924.htm
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.